Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genentech to study atezolizumab with Immune's CMB305 in soft tissue sarcoma; terminated

Executive Summary

Immune Design Corp. will bring together its CMB305 with Genentech Inc.'s atezolizumab in a randomized Phase II trial that will test the safety and efficacy of the combination in soft tissue sarcoma.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Trial Collaborations

Related Companies

Advertisement
UsernamePublicRestriction

Register